SlideShare a Scribd company logo
GOOD
MORNING
WELCOME TO WEEKLY
MORNING PRESENTATION
Hypersensitivity pneumonitis: a complex lung
disease
PRESENTED BY
DR.MD.SHARIF AHSAN
RESIDENT(PULMONOLOGY)
PHASE-A
Background
• 1st described in early 1900s
Farmer’s lung: fermers who reported febrile
episodes after exposure to mouldy grains,hay or
straw
Reed and barbee in 1965
pigeon breeder’s lung:relationship between hp
and exposure to avian antigens
Hendrik and colleagues in 1978
Budgerigar fancier’s lung
DEFINITION
• Hypersensitivity pneumonitis (HP), also called
extrinsic allergic alveolitis, is a respiratory
syndrome involving the lung parenchyma and
specifically the alveoli, terminal bronchioli, and
alveolar interstitium, due to a delayed allergic
reaction.
• Such reaction is secondary to a repeated and
prolonged inhalation of different types of organic
dusts or other substances to which the patient is
sensitized and hyper responsive,
PREVALENCE
• In the US HP accounted for less than 2% of the
patients with interstitial lung disease (ILD),
whose yearly incidence was calculated to be
about 30 per 100,000 .
• In Europe, according to ILD registries, HP
affects from 4 to 15% of all ILD cases .
CAUSATIVE AGENT
• Hypersensitivity pneumonitis can be caused
by multiple agents that are present in work
places and in the home, such as microbes,
animal and plant proteins, organic and
inorganic chemicals.
CAUSATIVE AGENT....
Three main categories:
 Microbial agents
 Bacteria
 Farmer’s lung
 Bagassosis
 Mushroom
worker’s lung
 Fungi
 Wood pulp
worker’s lung
 Cheese washer
lung
 Ameba
 Humidifier lung
Animal proteins
Avian proteins
 Bird breeder’s lung
Urine,Serum,Pelts
 Animal handler’s
lung
Wheat weevil
Wheat weevil lung
 Chemicals
 Isocyanate
 TDI,MDI,HDI
 TMA
 Trimellitic
anhydride
8
9
PATHOGENESIS
Host factors:
 Host susceptibility (Genetic factors)or
resistance factors may influence individual
responses to inhaled antigens.
 Non smokers > smokers
Exposure factors:
 Ag concentration
 Duration of exposure
 Frequency & intermittency of exposure
 Particle size
 Use of respiratory protection
 Farmer's lung disease: winter
 Bird breeder's lung: summer 10
PATHOGENESIS....
Immunology:
 Repeated inhalation of antigens → sensitization →
immunology response(type III,IV) → influx of
neutrophiles → shift T lymphocytes
(~70%)(predominantly of CD8)(↓CD4/CD8 )
 ..DesktopHypersensitivity
Pneumonitis_HD.mp4 11
PATHOGENESIS....
12
CLINICAL FEATURES
13
• Depends upon nature of the inhaled dust,
such as antigenicity, particle size, intensity and
frequency of exposure to the antigens, the
immunological response of the host and
concomitant bacterial or viral infections.
• Clinically HP can be categorised into acute,
subacute, and chronic forms.
The acute form
• Presents after a high-level of exposure to the
offending antigen over a short period of time.
• Symptoms usually develop within 4 to 8 hours
and are similar to acute viral infection.
• Symptoms may include high fever up to 40 oC,
chills, myalgia, fatigue, dyspnoea, and non-
productive cough.
• Bibasilar end inspiratory rales are prominent
and may persist for weeks after the fever
subsides.
Subacute Form
• The symptoms are more insidious in the subacute
form of HP due to the repeated low-level exposure.
• progressive respiratory symptoms over weeks-to-
months without acute systemic symptoms as noted
with the acute form.
• Physical examination often reveals crepitant rales
and hypoxemia especially with exertion.
Chronic HP
• Results from prolonged and continuous exposure
to low-levels of antigens leading to irreversible
pulmonary damage without major acute attacks.
• Progressive dyspnoea, cough, malaise, weakness,
anorexia, and weight loss are common. Fever is
often not present.
• Interstitial fibrosis is prominent.
• Lung examination may demonstrate dry crackles,
but wheezing is uncommon.
 End-stage disease: cyanosis & right-sided
HF
Laboratory Diagnosis
 ↑ Specific IgG against the offending antigen
 ↑ ESR & CRP
 ↑ IgM , IgA, IgG
 ↑ ANA
 IgE:Normal
 Eosinophil count:Normal
 BAL fluid study: ↑Lymphocyte count
↑ IgG
17
PFT
 There is no single characteristic pattern of
pulmonary function abnormalities .
 Acute HP : restrictive pattern
 Subacute and chronic HP : air way obstruction or
mixed
 ↓ DLCO (most sensitive physiologic test in early HP )
18
CXR
Acute HP:
 Diffuse ground glass opacification
 Fine nodular or reticulonodular pattern( lower
lung field)
 Consolidation ( rarely )
Subacute HP:
 Reticulonodular pattern
Chronic HP:
 Fibrosis with upper lobe retraction
 Reticular opacity
 Volume loss
 Honeycombing
 Mediastinal lymphadenopathy (up to 50%) 19
Ground glass pattern
 Most common in acute HP (but may also be seen in
subacute and chronic HP)
 Middle lung zone
 PFT: restrictive , ↓DLCO
 May resolve with removal from exposure
20
Acute HP: pigeon breeder’s lung shows ground-glass
haziness and associated air-trapping
21
Airspace consolidation
 Only reported in
acute HP
 Bilateral ill-defined
areas of
consolidation
22
Subacute HP: bilateral alveolar and
reticular pattern
23
Centrilobular nodules
 Round, poorly defined, less than 5 mm in diameter
 Typically centrilobular
 Profuse throughout the lung,but a middle to lower
lung zone predominance.
 Most frequent HRCT finding in HP
 Centrilobular nodules + ground glass
opacification are highly suggestive for HP.
 PFT : May be normal
24
Fibrosis
 Chronic HP (subacute HP)
 Irregular linear opacities
 Traction bronchiectasis
 Honeycombing
25
Emphysema
 Chronic HP
 Emphysema occurred more commonly than
fibrosis in chronic farmer’s lung.
26
Chronic HP: upper lobe fibrosis
27
Chronic HP: farmer’s lung disease showing bibasilar
end-stage fibrosis
28
HRCT
 Sensitivity of HRCT is significantly better than CXR
 Ground glass
 Centrilobular nodules
 Fibrosis
 Emphysema
 Mediastinal lymphadenopathy (> 20 mm )
29
Centrilobular ground-glass nodules uniformly
distributed throughout the lung.
Lobular air-trapping also frequently present.
30
Multiple low density ill-defined centrilobularnodules
31
Extensive areas of grand-glass attenuation.
Decreased perfusion (arrows)representing
associated air-trapping.
32
Chronic HP: Honeycombing, intralobular and septal
fibrosis, architectural distorsion
33
Mosaic pattern
 Patchwork of regions of differing attenuation
 Due to patchy areas of ground glass or
airtrapping
34
Lung Biopsy
 Classic triad:
 Cellular bronchiolitis
 Lympho-plasmocytic interstitial infiltration
 Non-necrotizing granulomas
35
Diagnosis
 Temporal relationship between symptoms
and certain activities is often the first clue
to the diagnosis of HP
37
Clinical Prediction
• 1. Exposure to known offending antigen
• 2. Positive precipitating antibody to the
offending antigen
• 3. Recurrent episodes of symptoms
• 4. Respiratory crackles in physical examination
• 5. Symptoms occurring between 4 to 8 hours
after exposure
• 6. Weight loss
• Major Criteria (Four major criteria need
to be present)
• 1. H/O symptoms compatible with HP
• 2. Evidence of exposure to the offending antigen
by history or through detection in serum or BAL
fluid antibody
• 3. Changes of characteristic HP on chest
radiograph or HRCT of chest
• 4.BAL fluid lymphocytosis,
• 5. Demonstration of histologic changes consistent
with HP
• 6. Positive ‘natural challenge’ that produces
symptoms
Diagnostic criteria for hp:
Adapted from Schuyler and Cormier (1997)
Minor Criteria (Two minor criteria
need to be present)
• 1. Bibasilar rales
• 2. Decreased diffusion capacity
• 3. Arterial hypoxemia, either at rest or with
exercise
TREATMENT
 Cornerstone of therapy → removal from exposure
 Respirators are used when removal from exposure is
impossible.
 Oxygen (hypoxemic patients)
 Opoids:Control of cough
 Airflow limitation:
 Inhaled steroids
 β-agonists
 Oral corticosteroids (40–60 mg/day of oral prednisone)
in severe or progressive disease.
 In refractory cases:
 Cyclophosphamide & Azathioprine
 No evidence on the efficacy of anti-fibrotic agents in
the treatment of chronic HP. 41
PROGNOSIS
 The clinical course of HP is variable
 Acute HP generally resolves without sequelae
 But progressive impairment may occur with recurrent
attacks or with a single severe attack.
 Subacute or chronic forms of HP present with
insidious symptoms
 More subtle clinical abnormalities
 Frequently recognized later in the disease course
 Long-term mortality rates for patients with chronic
HP range from 1% to 10%.
42
Poor Prognostic factors
 Older Age
 Exposure for a longer period
 Greater intensity of exposure
 Digital clubbing
 Histologic pattern of NSIP or UIP
43
Take home message
• HP results from an exacerbated immunologic
response to inhaled antigens.
• Menifestation ranging from infection-like acute
symtoms to subacute &chronic interstitial disease
• When exposure to antigen persists,permanent lung
damage may occur
• 1st line Rx for HP is withdrawl of contact with the
offending Ag.
• Oral corticosteroids,depending on the severity of
presentation.
HYPERSENSITIVITY PNEUMONITIS
HYPERSENSITIVITY PNEUMONITIS

More Related Content

What's hot

NON RESOLVING PNEUMONIA
NON RESOLVING PNEUMONIANON RESOLVING PNEUMONIA
NON RESOLVING PNEUMONIA
SURABHI SUSHMA REDDY
 
Steroid resistent asthma
Steroid resistent asthmaSteroid resistent asthma
Steroid resistent asthma
naser21021
 
PULMONARY EOSINOPHILIAS
PULMONARY EOSINOPHILIASPULMONARY EOSINOPHILIAS
PULMONARY EOSINOPHILIAS
Ashutosh Pakale
 
Idiopathic pulmonary fibrosis copy
Idiopathic pulmonary fibrosis   copyIdiopathic pulmonary fibrosis   copy
Idiopathic pulmonary fibrosis copyAdetunji Adesegun
 
Pulmonary Function Testing
Pulmonary Function TestingPulmonary Function Testing
Pulmonary Function Testing
Dr Riham Hazem Raafat
 
Bronchiectasis.
Bronchiectasis.Bronchiectasis.
Bronchiectasis.
Davis Kurian
 
Obesity Hypoventilation Syndrome
Obesity Hypoventilation Syndrome Obesity Hypoventilation Syndrome
Obesity Hypoventilation Syndrome
Ade Wijaya
 
Respiratory failure
Respiratory failureRespiratory failure
Respiratory failure
Vijay Sal
 
Practical approach to Idiopathic Pulmonary Fibrosis.
Practical approach to Idiopathic Pulmonary Fibrosis.Practical approach to Idiopathic Pulmonary Fibrosis.
Practical approach to Idiopathic Pulmonary Fibrosis.
Hiba Ashibany
 
Pulmonary hypertension
Pulmonary hypertensionPulmonary hypertension
Pulmonary hypertension
Md Shahid Iqubal
 
Bronchiectasis final
Bronchiectasis final Bronchiectasis final
Bronchiectasis final
Dr.Manish Kumar
 
interstitial lung diseases
interstitial lung diseasesinterstitial lung diseases
interstitial lung diseases
DrBasith Lateef
 
atypical pneumonia.pptx
atypical pneumonia.pptxatypical pneumonia.pptx
atypical pneumonia.pptx
Rasika Deshmukh
 
Pulmonary eosinophilic infiltrates
Pulmonary eosinophilic infiltratesPulmonary eosinophilic infiltrates
Pulmonary eosinophilic infiltrates
Firoz Hakkim
 
Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis (IPF)
Spectrum Health System
 
Hospital acquired pneumonia
Hospital acquired pneumoniaHospital acquired pneumonia
Hospital acquired pneumonia
MEEQAT HOSPITAL
 
Abpa
AbpaAbpa
Interstitial lung diseases
Interstitial lung diseases Interstitial lung diseases
Interstitial lung diseases
Dr.Manish Kumar
 
Eosinophillic lung diseases
Eosinophillic lung diseasesEosinophillic lung diseases
Eosinophillic lung diseasesAnkit Mittal
 

What's hot (20)

NON RESOLVING PNEUMONIA
NON RESOLVING PNEUMONIANON RESOLVING PNEUMONIA
NON RESOLVING PNEUMONIA
 
Steroid resistent asthma
Steroid resistent asthmaSteroid resistent asthma
Steroid resistent asthma
 
PULMONARY EOSINOPHILIAS
PULMONARY EOSINOPHILIASPULMONARY EOSINOPHILIAS
PULMONARY EOSINOPHILIAS
 
Idiopathic pulmonary fibrosis copy
Idiopathic pulmonary fibrosis   copyIdiopathic pulmonary fibrosis   copy
Idiopathic pulmonary fibrosis copy
 
Pulmonary Function Testing
Pulmonary Function TestingPulmonary Function Testing
Pulmonary Function Testing
 
Bronchiectasis.
Bronchiectasis.Bronchiectasis.
Bronchiectasis.
 
Obesity Hypoventilation Syndrome
Obesity Hypoventilation Syndrome Obesity Hypoventilation Syndrome
Obesity Hypoventilation Syndrome
 
Respiratory failure
Respiratory failureRespiratory failure
Respiratory failure
 
Practical approach to Idiopathic Pulmonary Fibrosis.
Practical approach to Idiopathic Pulmonary Fibrosis.Practical approach to Idiopathic Pulmonary Fibrosis.
Practical approach to Idiopathic Pulmonary Fibrosis.
 
Pulmonary hypertension
Pulmonary hypertensionPulmonary hypertension
Pulmonary hypertension
 
Bronchiectasis final
Bronchiectasis final Bronchiectasis final
Bronchiectasis final
 
interstitial lung diseases
interstitial lung diseasesinterstitial lung diseases
interstitial lung diseases
 
atypical pneumonia.pptx
atypical pneumonia.pptxatypical pneumonia.pptx
atypical pneumonia.pptx
 
Pulmonary eosinophilic infiltrates
Pulmonary eosinophilic infiltratesPulmonary eosinophilic infiltrates
Pulmonary eosinophilic infiltrates
 
Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis (IPF)
 
Hospital acquired pneumonia
Hospital acquired pneumoniaHospital acquired pneumonia
Hospital acquired pneumonia
 
Abpa
AbpaAbpa
Abpa
 
Hypersensitivity Pneumonitis
Hypersensitivity  PneumonitisHypersensitivity  Pneumonitis
Hypersensitivity Pneumonitis
 
Interstitial lung diseases
Interstitial lung diseases Interstitial lung diseases
Interstitial lung diseases
 
Eosinophillic lung diseases
Eosinophillic lung diseasesEosinophillic lung diseases
Eosinophillic lung diseases
 

Similar to HYPERSENSITIVITY PNEUMONITIS

Presentation by S.K Jindal on Hypersensitivity Pneumonitis: Approach to diagn...
Presentation by S.K Jindal on Hypersensitivity Pneumonitis: Approach to diagn...Presentation by S.K Jindal on Hypersensitivity Pneumonitis: Approach to diagn...
Presentation by S.K Jindal on Hypersensitivity Pneumonitis: Approach to diagn...
Jindal Chest Clinic
 
Ckd chief (2)
Ckd chief (2)Ckd chief (2)
Ckd chief (2)
Rajiv Lal
 
BRONCHO PNEUMONIA PRESESNTATION.pptx
BRONCHO PNEUMONIA PRESESNTATION.pptxBRONCHO PNEUMONIA PRESESNTATION.pptx
BRONCHO PNEUMONIA PRESESNTATION.pptx
eguyujohn1
 
Pneumonia by dr zohaib pgt med
Pneumonia by dr zohaib pgt medPneumonia by dr zohaib pgt med
Pneumonia by dr zohaib pgt med
zohaibalikan
 
farmer's lung disease
farmer's lung diseasefarmer's lung disease
farmer's lung disease
maask friend
 
Ards(En终)
Ards(En终)Ards(En终)
Ards(En终)
Deep Deep
 
Community acquired pneumonia
Community acquired pneumoniaCommunity acquired pneumonia
Community acquired pneumoniaSaba Khan
 
Gwen med surg pneumonia final
Gwen med surg pneumonia finalGwen med surg pneumonia final
Gwen med surg pneumonia final
Gwenneth Zoelie Nongkhlaw
 
باثوهObstructiveLungDiseaseI-1.pptx
باثوهObstructiveLungDiseaseI-1.pptxباثوهObstructiveLungDiseaseI-1.pptx
باثوهObstructiveLungDiseaseI-1.pptx
TofikMohammed3
 
Respiratory disorder. Part 2.ppt
Respiratory disorder. Part 2.pptRespiratory disorder. Part 2.ppt
Respiratory disorder. Part 2.ppt
Aryansinha20
 
Happy hypoxia,
Happy hypoxia, Happy hypoxia,
Happy hypoxia,
Ankita Chauhan
 
Pulmonary_inections[1].pptx
Pulmonary_inections[1].pptxPulmonary_inections[1].pptx
Pulmonary_inections[1].pptx
khaalidmohamed6
 
Pulmonary inections.pptx
Pulmonary inections.pptxPulmonary inections.pptx
Pulmonary inections.pptx
yusufArashid
 
SEVER Viral pneumonia last
SEVER Viral pneumonia lastSEVER Viral pneumonia last
SEVER Viral pneumonia last
Dr.Tarek Sabry
 
Respirtory part2
Respirtory part2Respirtory part2
Respirtory part2lam808
 
interstitial lung disease (ilD)
interstitial lung disease (ilD)interstitial lung disease (ilD)
interstitial lung disease (ilD)
Mahamad Jamal
 
Pneumonia
PneumoniaPneumonia
Pneumonia
hemin sab
 

Similar to HYPERSENSITIVITY PNEUMONITIS (20)

Presentation by S.K Jindal on Hypersensitivity Pneumonitis: Approach to diagn...
Presentation by S.K Jindal on Hypersensitivity Pneumonitis: Approach to diagn...Presentation by S.K Jindal on Hypersensitivity Pneumonitis: Approach to diagn...
Presentation by S.K Jindal on Hypersensitivity Pneumonitis: Approach to diagn...
 
Ckd chief (2)
Ckd chief (2)Ckd chief (2)
Ckd chief (2)
 
BRONCHO PNEUMONIA PRESESNTATION.pptx
BRONCHO PNEUMONIA PRESESNTATION.pptxBRONCHO PNEUMONIA PRESESNTATION.pptx
BRONCHO PNEUMONIA PRESESNTATION.pptx
 
Pneumonia by dr zohaib pgt med
Pneumonia by dr zohaib pgt medPneumonia by dr zohaib pgt med
Pneumonia by dr zohaib pgt med
 
farmer's lung disease
farmer's lung diseasefarmer's lung disease
farmer's lung disease
 
Farmer’s lung
Farmer’s lungFarmer’s lung
Farmer’s lung
 
Ards(En终)
Ards(En终)Ards(En终)
Ards(En终)
 
Ards(En终)
Ards(En终)Ards(En终)
Ards(En终)
 
Community acquired pneumonia
Community acquired pneumoniaCommunity acquired pneumonia
Community acquired pneumonia
 
Gwen med surg pneumonia final
Gwen med surg pneumonia finalGwen med surg pneumonia final
Gwen med surg pneumonia final
 
باثوهObstructiveLungDiseaseI-1.pptx
باثوهObstructiveLungDiseaseI-1.pptxباثوهObstructiveLungDiseaseI-1.pptx
باثوهObstructiveLungDiseaseI-1.pptx
 
Respiratory disorder. Part 2.ppt
Respiratory disorder. Part 2.pptRespiratory disorder. Part 2.ppt
Respiratory disorder. Part 2.ppt
 
Happy hypoxia,
Happy hypoxia, Happy hypoxia,
Happy hypoxia,
 
Pulmonary_inections[1].pptx
Pulmonary_inections[1].pptxPulmonary_inections[1].pptx
Pulmonary_inections[1].pptx
 
Pulmonary inections.pptx
Pulmonary inections.pptxPulmonary inections.pptx
Pulmonary inections.pptx
 
SEVER Viral pneumonia last
SEVER Viral pneumonia lastSEVER Viral pneumonia last
SEVER Viral pneumonia last
 
Respirtory part2
Respirtory part2Respirtory part2
Respirtory part2
 
COPD ppt
COPD pptCOPD ppt
COPD ppt
 
interstitial lung disease (ilD)
interstitial lung disease (ilD)interstitial lung disease (ilD)
interstitial lung disease (ilD)
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 

More from DR.SHARIF AHSAN

Non Tuberculous Mycobacteria
Non Tuberculous MycobacteriaNon Tuberculous Mycobacteria
Non Tuberculous Mycobacteria
DR.SHARIF AHSAN
 
Extra pulmonary TB
Extra pulmonary TBExtra pulmonary TB
Extra pulmonary TB
DR.SHARIF AHSAN
 
Sarcoidosis
SarcoidosisSarcoidosis
Sarcoidosis
DR.SHARIF AHSAN
 
Primary hypertrophic osteoarthropathy (hpoa)
Primary hypertrophic osteoarthropathy (hpoa)Primary hypertrophic osteoarthropathy (hpoa)
Primary hypertrophic osteoarthropathy (hpoa)
DR.SHARIF AHSAN
 
Evaluation of cough
Evaluation of coughEvaluation of cough
Evaluation of cough
DR.SHARIF AHSAN
 

More from DR.SHARIF AHSAN (6)

Cystic fibrosis
Cystic fibrosisCystic fibrosis
Cystic fibrosis
 
Non Tuberculous Mycobacteria
Non Tuberculous MycobacteriaNon Tuberculous Mycobacteria
Non Tuberculous Mycobacteria
 
Extra pulmonary TB
Extra pulmonary TBExtra pulmonary TB
Extra pulmonary TB
 
Sarcoidosis
SarcoidosisSarcoidosis
Sarcoidosis
 
Primary hypertrophic osteoarthropathy (hpoa)
Primary hypertrophic osteoarthropathy (hpoa)Primary hypertrophic osteoarthropathy (hpoa)
Primary hypertrophic osteoarthropathy (hpoa)
 
Evaluation of cough
Evaluation of coughEvaluation of cough
Evaluation of cough
 

Recently uploaded

Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Dr KHALID B.M
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
MedicoseAcademics
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
kevinkariuki227
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
Sujoy Dasgupta
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
i3 Health
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
jval Landero
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
addon Scans
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
Rohit chaurpagar
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
Jim Jacob Roy
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
Savita Shen $i11
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
Catherine Liao
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 

Recently uploaded (20)

Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 

HYPERSENSITIVITY PNEUMONITIS

  • 3. Hypersensitivity pneumonitis: a complex lung disease PRESENTED BY DR.MD.SHARIF AHSAN RESIDENT(PULMONOLOGY) PHASE-A
  • 4. Background • 1st described in early 1900s Farmer’s lung: fermers who reported febrile episodes after exposure to mouldy grains,hay or straw Reed and barbee in 1965 pigeon breeder’s lung:relationship between hp and exposure to avian antigens Hendrik and colleagues in 1978 Budgerigar fancier’s lung
  • 5. DEFINITION • Hypersensitivity pneumonitis (HP), also called extrinsic allergic alveolitis, is a respiratory syndrome involving the lung parenchyma and specifically the alveoli, terminal bronchioli, and alveolar interstitium, due to a delayed allergic reaction. • Such reaction is secondary to a repeated and prolonged inhalation of different types of organic dusts or other substances to which the patient is sensitized and hyper responsive,
  • 6. PREVALENCE • In the US HP accounted for less than 2% of the patients with interstitial lung disease (ILD), whose yearly incidence was calculated to be about 30 per 100,000 . • In Europe, according to ILD registries, HP affects from 4 to 15% of all ILD cases .
  • 7. CAUSATIVE AGENT • Hypersensitivity pneumonitis can be caused by multiple agents that are present in work places and in the home, such as microbes, animal and plant proteins, organic and inorganic chemicals.
  • 8. CAUSATIVE AGENT.... Three main categories:  Microbial agents  Bacteria  Farmer’s lung  Bagassosis  Mushroom worker’s lung  Fungi  Wood pulp worker’s lung  Cheese washer lung  Ameba  Humidifier lung Animal proteins Avian proteins  Bird breeder’s lung Urine,Serum,Pelts  Animal handler’s lung Wheat weevil Wheat weevil lung  Chemicals  Isocyanate  TDI,MDI,HDI  TMA  Trimellitic anhydride 8
  • 9. 9
  • 10. PATHOGENESIS Host factors:  Host susceptibility (Genetic factors)or resistance factors may influence individual responses to inhaled antigens.  Non smokers > smokers Exposure factors:  Ag concentration  Duration of exposure  Frequency & intermittency of exposure  Particle size  Use of respiratory protection  Farmer's lung disease: winter  Bird breeder's lung: summer 10
  • 11. PATHOGENESIS.... Immunology:  Repeated inhalation of antigens → sensitization → immunology response(type III,IV) → influx of neutrophiles → shift T lymphocytes (~70%)(predominantly of CD8)(↓CD4/CD8 )  ..DesktopHypersensitivity Pneumonitis_HD.mp4 11
  • 13. CLINICAL FEATURES 13 • Depends upon nature of the inhaled dust, such as antigenicity, particle size, intensity and frequency of exposure to the antigens, the immunological response of the host and concomitant bacterial or viral infections. • Clinically HP can be categorised into acute, subacute, and chronic forms.
  • 14. The acute form • Presents after a high-level of exposure to the offending antigen over a short period of time. • Symptoms usually develop within 4 to 8 hours and are similar to acute viral infection. • Symptoms may include high fever up to 40 oC, chills, myalgia, fatigue, dyspnoea, and non- productive cough. • Bibasilar end inspiratory rales are prominent and may persist for weeks after the fever subsides.
  • 15. Subacute Form • The symptoms are more insidious in the subacute form of HP due to the repeated low-level exposure. • progressive respiratory symptoms over weeks-to- months without acute systemic symptoms as noted with the acute form. • Physical examination often reveals crepitant rales and hypoxemia especially with exertion.
  • 16. Chronic HP • Results from prolonged and continuous exposure to low-levels of antigens leading to irreversible pulmonary damage without major acute attacks. • Progressive dyspnoea, cough, malaise, weakness, anorexia, and weight loss are common. Fever is often not present. • Interstitial fibrosis is prominent. • Lung examination may demonstrate dry crackles, but wheezing is uncommon.  End-stage disease: cyanosis & right-sided HF
  • 17. Laboratory Diagnosis  ↑ Specific IgG against the offending antigen  ↑ ESR & CRP  ↑ IgM , IgA, IgG  ↑ ANA  IgE:Normal  Eosinophil count:Normal  BAL fluid study: ↑Lymphocyte count ↑ IgG 17
  • 18. PFT  There is no single characteristic pattern of pulmonary function abnormalities .  Acute HP : restrictive pattern  Subacute and chronic HP : air way obstruction or mixed  ↓ DLCO (most sensitive physiologic test in early HP ) 18
  • 19. CXR Acute HP:  Diffuse ground glass opacification  Fine nodular or reticulonodular pattern( lower lung field)  Consolidation ( rarely ) Subacute HP:  Reticulonodular pattern Chronic HP:  Fibrosis with upper lobe retraction  Reticular opacity  Volume loss  Honeycombing  Mediastinal lymphadenopathy (up to 50%) 19
  • 20. Ground glass pattern  Most common in acute HP (but may also be seen in subacute and chronic HP)  Middle lung zone  PFT: restrictive , ↓DLCO  May resolve with removal from exposure 20
  • 21. Acute HP: pigeon breeder’s lung shows ground-glass haziness and associated air-trapping 21
  • 22. Airspace consolidation  Only reported in acute HP  Bilateral ill-defined areas of consolidation 22
  • 23. Subacute HP: bilateral alveolar and reticular pattern 23
  • 24. Centrilobular nodules  Round, poorly defined, less than 5 mm in diameter  Typically centrilobular  Profuse throughout the lung,but a middle to lower lung zone predominance.  Most frequent HRCT finding in HP  Centrilobular nodules + ground glass opacification are highly suggestive for HP.  PFT : May be normal 24
  • 25. Fibrosis  Chronic HP (subacute HP)  Irregular linear opacities  Traction bronchiectasis  Honeycombing 25
  • 26. Emphysema  Chronic HP  Emphysema occurred more commonly than fibrosis in chronic farmer’s lung. 26
  • 27. Chronic HP: upper lobe fibrosis 27
  • 28. Chronic HP: farmer’s lung disease showing bibasilar end-stage fibrosis 28
  • 29. HRCT  Sensitivity of HRCT is significantly better than CXR  Ground glass  Centrilobular nodules  Fibrosis  Emphysema  Mediastinal lymphadenopathy (> 20 mm ) 29
  • 30. Centrilobular ground-glass nodules uniformly distributed throughout the lung. Lobular air-trapping also frequently present. 30
  • 31. Multiple low density ill-defined centrilobularnodules 31
  • 32. Extensive areas of grand-glass attenuation. Decreased perfusion (arrows)representing associated air-trapping. 32
  • 33. Chronic HP: Honeycombing, intralobular and septal fibrosis, architectural distorsion 33
  • 34. Mosaic pattern  Patchwork of regions of differing attenuation  Due to patchy areas of ground glass or airtrapping 34
  • 35. Lung Biopsy  Classic triad:  Cellular bronchiolitis  Lympho-plasmocytic interstitial infiltration  Non-necrotizing granulomas 35
  • 36.
  • 37. Diagnosis  Temporal relationship between symptoms and certain activities is often the first clue to the diagnosis of HP 37
  • 38. Clinical Prediction • 1. Exposure to known offending antigen • 2. Positive precipitating antibody to the offending antigen • 3. Recurrent episodes of symptoms • 4. Respiratory crackles in physical examination • 5. Symptoms occurring between 4 to 8 hours after exposure • 6. Weight loss
  • 39. • Major Criteria (Four major criteria need to be present) • 1. H/O symptoms compatible with HP • 2. Evidence of exposure to the offending antigen by history or through detection in serum or BAL fluid antibody • 3. Changes of characteristic HP on chest radiograph or HRCT of chest • 4.BAL fluid lymphocytosis, • 5. Demonstration of histologic changes consistent with HP • 6. Positive ‘natural challenge’ that produces symptoms Diagnostic criteria for hp: Adapted from Schuyler and Cormier (1997)
  • 40. Minor Criteria (Two minor criteria need to be present) • 1. Bibasilar rales • 2. Decreased diffusion capacity • 3. Arterial hypoxemia, either at rest or with exercise
  • 41. TREATMENT  Cornerstone of therapy → removal from exposure  Respirators are used when removal from exposure is impossible.  Oxygen (hypoxemic patients)  Opoids:Control of cough  Airflow limitation:  Inhaled steroids  β-agonists  Oral corticosteroids (40–60 mg/day of oral prednisone) in severe or progressive disease.  In refractory cases:  Cyclophosphamide & Azathioprine  No evidence on the efficacy of anti-fibrotic agents in the treatment of chronic HP. 41
  • 42. PROGNOSIS  The clinical course of HP is variable  Acute HP generally resolves without sequelae  But progressive impairment may occur with recurrent attacks or with a single severe attack.  Subacute or chronic forms of HP present with insidious symptoms  More subtle clinical abnormalities  Frequently recognized later in the disease course  Long-term mortality rates for patients with chronic HP range from 1% to 10%. 42
  • 43. Poor Prognostic factors  Older Age  Exposure for a longer period  Greater intensity of exposure  Digital clubbing  Histologic pattern of NSIP or UIP 43
  • 44. Take home message • HP results from an exacerbated immunologic response to inhaled antigens. • Menifestation ranging from infection-like acute symtoms to subacute &chronic interstitial disease • When exposure to antigen persists,permanent lung damage may occur • 1st line Rx for HP is withdrawl of contact with the offending Ag. • Oral corticosteroids,depending on the severity of presentation.